Medical Developments International Ltd (ASX: MVP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Medical Developments International Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $45.06 million
P/E Ratio 1,000.00
Dividend Yield 0.00%
Shares Outstanding 112.66 million
Earnings per share -0.463
Dividend per share 0.04
Year To Date Return -45.29%
Earnings Yield 0.10%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Medical Developments International Ltd (ASX: MVP)
    Latest News

    a woman
    ⏸️ Investing

    6 stocks slammed on the ASX today

    S&P/ASX 300 (INDEXASX:XKO) drops 0.2%, but these 6 stocks were hammered

    Read more »

    a woman
    ⏸️ Investing

    4 ASX stocks hammered down today

    The ASX's All Ordinaries index sinks 0.5%, but these four were dealt a bigger blow

    Read more »

    a woman
    ⏸️ Investing

    9 juicy health care stocks to add to your portfolio: Part 2

    Overlooked by the market, here are another 5 profitable health care stocks to add to your watchlist

    Read more »

    a woman
    ⏸️ Investing

    Medical Developments International Ltd profit soars: Should you buy?

    Medical Developments International Ltd (ASX:MVP) reported stellar earning results today. With huge international expansion plans, is the stock a buy?

    Read more »

    ⏸️ Investing

    5 biotech stocks to add excitement to your portfolio

    3 of them are even growing profits at a strong pace

    Read more »

    Frequently Asked Questions

    Medical Developments International has not paid a Dividend since 2019.

    Medical Developments International Ltd listed on the ASX on 15 December 2003.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    05 Mar 2020 $0.0200 100.00% Interim 17 Apr 2020
    03 Sep 2019 $0.0200 100.00% Final 04 Oct 2019
    07 Mar 2019 $0.0200 100.00% Interim 17 Apr 2019
    30 Aug 2018 $0.0200 100.00% Final 05 Oct 2018
    02 Mar 2018 $0.0200 100.00% Interim 13 Apr 2018
    31 Aug 2017 $0.0000 100.00% Final 06 Oct 2017
    03 Mar 2017 $0.0200 100.00% Interim 10 Apr 2017
    01 Sep 2016 $0.0200 100.00% Final 07 Oct 2016
    02 Mar 2016 $0.0200 100.00% Interim 08 Apr 2016
    02 Sep 2013 $0.0200 100.00% Final 11 Oct 2013
    27 Feb 2013 $0.0300 100.00% Interim 11 Apr 2013
    28 Feb 2012 $0.0300 100.00% Interim 11 Apr 2012
    31 Aug 2011 $0.0300 100.00% Final 10 Oct 2011

    MVP ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Medical Developments International Ltd

    Medical Developments International Ltd (ASX: MVP) is an Australian- based pharmaceutical company. It manufactures and distributes pharmaceutical drugs covering pain management, asthma, and resuscitation, as well as medical and veterinary equipment.

    The company has three business units: pharmaceuticals, medical devices, and veterinary products. The majority of its revenue comes from its pharmaceuticals segment which produces and sells the pain relief drug Penthrox within Australia, New Zealand, and the United Kingdom, as well as some sales in other countries. 

     

     

    MVP Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Dec 2024 $0.41 $0.01 2.53% 72,946 $0.40 $0.41 $0.40
    19 Dec 2024 $0.40 $-0.01 -2.47% 81,698 $0.41 $0.41 $0.40
    18 Dec 2024 $0.41 $0.00 0.00% 35,409 $0.41 $0.41 $0.41
    17 Dec 2024 $0.41 $0.00 0.00% 16,283 $0.41 $0.42 $0.41
    16 Dec 2024 $0.41 $0.00 0.00% 12,284 $0.41 $0.42 $0.41
    13 Dec 2024 $0.41 $-0.01 -2.41% 152,952 $0.41 $0.41 $0.41
    12 Dec 2024 $0.42 $0.00 0.00% 240,699 $0.42 $0.45 $0.40
    11 Dec 2024 $0.42 $-0.01 -2.35% 60,629 $0.42 $0.42 $0.42
    10 Dec 2024 $0.43 $0.01 2.38% 103,606 $0.42 $0.43 $0.42
    09 Dec 2024 $0.42 $0.01 2.41% 71,671 $0.42 $0.42 $0.42
    06 Dec 2024 $0.42 $-0.01 -2.35% 78,602 $0.43 $0.43 $0.42
    05 Dec 2024 $0.43 $0.01 2.41% 49,413 $0.43 $0.44 $0.43
    04 Dec 2024 $0.42 $0.01 2.44% 74,115 $0.41 $0.44 $0.41
    03 Dec 2024 $0.41 $-0.01 -2.41% 157,450 $0.42 $0.42 $0.41
    02 Dec 2024 $0.42 $-0.01 -2.38% 172,881 $0.42 $0.43 $0.42
    29 Nov 2024 $0.42 $0.01 2.44% 111,432 $0.42 $0.43 $0.41
    28 Nov 2024 $0.41 $-0.01 -2.41% 147,047 $0.42 $0.42 $0.41
    27 Nov 2024 $0.42 $0.00 0.00% 92,906 $0.42 $0.43 $0.42
    26 Nov 2024 $0.42 $0.00 0.00% 219,275 $0.42 $0.43 $0.42
    25 Nov 2024 $0.42 $-0.01 -2.38% 126,611 $0.43 $0.43 $0.42

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    28 Aug 2024 Christine Emmanuel-Donnelly Buy 26,478 $10,061
    As advised by the company. Participation in capital Raise
    28 Aug 2024 Gordon Naylor Issued 264,782 $100,617
    Rights issue.
    06 Aug 2024 Gordon Naylor Buy 93,453 $35,512
    As advised by the company. Participation in capital Raise
    06 Aug 2024 Leon Hoare Buy 8,436 $3,205
    As advised by the company. Participation in capital Raise
    06 Aug 2024 Richard Betts Buy 3,181 $1,208
    As advised by the company. Participation in capital Raise
    06 Aug 2024 Maria (Mary) Sontrop Buy 2,801 $1,064
    As advised by the company. Participation in capital Raise
    06 Aug 2024 Christine Emmanuel-Donnelly Buy 7,684 $2,919
    As advised by the company. Participation in capital Raise
    06 Aug 2024 Russell Basser Buy 2,160 $820
    As advised by the company. Participation in capital Raise
    03 Apr 2024 Russell Basser Buy 15,873 $9,761
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Leon Hoare Non-Executive Director Sep 2013
    Mr Hoare is a commercial leader with expertise across multiple Life Science sectors. Previously, he was Managing Director of Smith & Nephew (S&N) ANZ, one of S&N's largest global subsidiaries outside the USA. He served as President of S&N's Asia Pacific Advanced Wound Management (AWM) business for 5 years and was a member of the Global Executive Management for the AWM Division (as one of three Regional Presidents). In his 24 years with S&N, he also held roles in marketing, divisional and general management. His career has also included a senior role at Bristol-Myers Squibb, and as Vice-Chair of the board of Australia's peak medical device industry body, Medical Technology Association of Australia. Mr Hoare is also the Chair of the Human Resources Committee. He is member of Human Resource Committee.
    Mr Richard Betts Non-Executive Director May 2021
    Mr Betts is an experienced executive who has held senior roles with ASX listed entities over 25 years. He was previously Chief Financial Officer at Pact Group Holdings Ltd for 6 years. Prior to that he held executive finance and general management roles at Orica Limited. These roles provided Mr Betts with a deep understanding of working in various jurisdictions, including North America, Europe and Asia. Mr Betts has financial and governance experience within international manufacturing environments. Mr Betts is Chair of the Risk and Continuous Disclosure Committee.
    Ms Christine Emmanuel-Donnelly Non-Executive Director May 2020
    Ms Emmanuel-Donnelly is an experienced IP and business development professional having 35 years of experience locally and internationally. Ms Emmanuel-Donnelly is a former Executive Manager of Business Development and Commercial at the CSIRO, where she led the management of CSIRO's IP team and IP portfolio for 14 years and managed the CSIRO equity portfolio for over 5 years. Prior to this role, Ms Emmanuel-Donnelly was in-house IP Counsel for Unilever in the UK and practised as a patent and trademark attorney for Wilson Gunn (UK), Davies Collison Cave and Griffith Hack in Melbourne. She is member of Risk Committee.
    Mr Gordon Naylor Non-Executive DirectorNon-Executive Chairman Oct 2020
    Mr Naylor for over 30 years he was a key part of the internationalisation of CSL, holding a range of business and functional leadership roles including Chief Financial Officer. At the time of his retirement from CSL, he was the President of Seqirus where he led the 3-year turnaround of that business into one of the most successful vaccine companies in the world. He is member of Human Resource and Continuous Disclosure Committee.
    Dr Russell Basser Non-Executive Director Aug 2023
    Dr Basser is a physician, with over 30 years of international medical and biopharmaceutical experience. Dr Basser worked as a medical oncologist in Melbourne prior to joining CSL in 2001. During his 21 years at CSL, he held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. Dr Basser has expertise in international drug and vaccine development and spent several years based in the USA. He is member of Human Resource Committee.
    Mr Brent MacGregor Chief Executive Officer Nov 2020
    -
    Ms Tara Eaton Company SecretaryGeneral Counsel Aug 2022
    -
    A James CFO
    -
    Brent MacGregor Chief Executive Officer
    -
    Tara Eaton Company SecretaryGeneral Counsel
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 10,683,815 9.48%
    Citicorp Nominees Pty Limited 7,576,013 6.72%
    HSBC Custody Nominees (Australia) Limited 6,500,532 5.77%
    Lawn Views Pty Ltd <Angela Williams Family A/C> 5,904,120 5.24%
    Moggs Creek Pty Ltd <Moggs Creek Super A/C> 5,278,615 4.69%
    Ubs Nominees Pty Ltd 4,920,177 4.37%
    Netwealth Investments Limited <Wrap Services A/C> 3,650,550 3.24%
    Payne Media Pty Ltd 2,937,127 2.61%
    Mirrabooka Investments Limited 2,592,084 2.30%
    Dr Russell Kay Hancock 2,120,000 1.88%
    HSBC Custody Nominees (Australia) Limited A/C 2 1,367,424 1.21%
    BNP Paribas Nominees Pty Ltd <Clearstream> 1,364,260 1.21%
    Naylor Stewart Investments Pty Ltd <Naylor Stewart Family A/C> 1,045,113 0.93%
    Kidder Peabody Pty Ltd 1,042,945 0.93%
    Merrill Lynch (Australia) Nominees Pty Limited 867,848 0.77%
    Mr David Williams <William Street A/C> 861,817 0.76%
    Neweconomy Com Au Nominees Pty Limited <900 Account> 861,039 0.76%
    Mr Alistair David Strong 750,000 0.67%
    National Nominees Limited 748,009 0.66%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 733,300 0.65%

    Profile

    since

    Note